GMVDF logo

G Medical Innovations Holdings Ltd (GMVDF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

G Medical Innovations Holdings Ltd (GMVDF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 44/100

G Medical Innovations Holdings Ltd (GMVDF) Resumen de Asistencia Médica y Tuberías

Empleados84
Sede CentralRehovot, Israel

G Medical Innovations Holdings Ltd, based in Israel, develops and markets mobile health and telemedicine solutions, including the Prizma multi-sensor device and the Extended Holter Patch System. The company focuses on continuous vital signs monitoring and ECG data capture, operating within the competitive medical devices sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

G Medical Innovations Holdings Ltd presents a compelling, albeit high-risk, investment opportunity within the burgeoning mobile health and telemedicine market. The company's Prizma and Extended Holter Patch System address the increasing need for remote patient monitoring and continuous health data capture. However, with a market capitalization of $0.00B and negative free cash flow of $-0.00B, the company's financial stability is a significant concern. A beta of 1523.14 indicates extreme volatility relative to the market. Growth hinges on successful commercialization of its products and expansion of its monitoring services. Investors should carefully weigh the potential for growth in the telemedicine sector against the company's current financial challenges and OTC market risks. The company's gross margin stands at 17.7%.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • G Medical Innovations Holdings Ltd operates in the rapidly growing mobile health and telemedicine market.
  • The company's Prizma device offers multi-sensor vital signs monitoring, catering to proactive health management.
  • The Extended Holter Patch System provides extended electrocardiography (ECG) data capture for cardiac monitoring.
  • The company's gross margin is 17.7%.
  • G Medical Innovations Holdings Ltd has a beta of 1523.14, indicating very high volatility.

Competidores y Pares

Fortalezas

  • Innovative mobile health and telemedicine solutions.
  • Integrated platform combining devices and monitoring services.
  • Focus on continuous vital signs monitoring.
  • Proprietary technology in the Prizma device.

Debilidades

  • Early commercial stage company with limited market presence.
  • Negative free cash flow and limited financial resources.
  • High beta indicating significant stock volatility.
  • Reliance on OTC market for trading.

Catalizadores

  • Upcoming: Regulatory approvals for Prizma and Extended Holter Patch System in new markets.
  • Upcoming: Strategic partnerships with healthcare providers and insurance companies.
  • Ongoing: Expansion of monitoring services to new diagnostic facilities.
  • Ongoing: Development of advanced analytics and AI capabilities for remote patient monitoring.
  • Ongoing: Commercialization of new applications for the Extended Holter Patch System.

Riesgos

  • Potential: Intense competition in the medical device and telehealth industries.
  • Potential: Regulatory hurdles and reimbursement challenges.
  • Ongoing: Limited financial resources and negative free cash flow.
  • Ongoing: High stock volatility due to OTC market trading.
  • Potential: Technological obsolescence.

Oportunidades de crecimiento

  • Growth opportunity 1: Expansion of the Prizma platform into chronic disease management represents a significant growth opportunity. By integrating additional sensors and algorithms, the Prizma device can be tailored to monitor specific conditions such as diabetes, hypertension, and heart failure. The market for remote chronic disease management is projected to reach $60 billion by 2028, driven by the increasing prevalence of chronic diseases and the need for cost-effective monitoring solutions. G Medical Innovations can leverage its existing technology and partnerships to capture a share of this market, offering personalized and proactive healthcare management.
  • Growth opportunity 2: Strategic partnerships with healthcare providers and insurance companies can accelerate adoption of G Medical Innovations' solutions. By collaborating with hospitals, clinics, and telehealth platforms, the company can integrate its devices and monitoring services into existing healthcare workflows. Partnerships with insurance companies can facilitate reimbursement for remote patient monitoring, making the solutions more accessible to patients. The market for remote patient monitoring is expected to reach $175 billion by 2027, driven by the increasing adoption of value-based care models and the need for cost-effective healthcare delivery.
  • Growth opportunity 3: Geographic expansion into new markets, particularly in Europe and Asia, offers substantial growth potential. By obtaining regulatory approvals and establishing distribution networks in these regions, G Medical Innovations can tap into new customer bases and revenue streams. The global market for mobile health is projected to reach $250 billion by 2025, with significant growth expected in emerging markets. G Medical Innovations can leverage its existing technology and partnerships to penetrate these markets, offering innovative solutions for remote patient monitoring and telemedicine.
  • Growth opportunity 4: Development of advanced analytics and artificial intelligence (AI) capabilities can enhance the value proposition of G Medical Innovations' solutions. By incorporating AI algorithms into its monitoring platform, the company can provide predictive insights and personalized recommendations to patients and healthcare providers. The market for AI in healthcare is projected to reach $45 billion by 2026, driven by the increasing availability of healthcare data and the need for more efficient and effective healthcare delivery. G Medical Innovations can leverage its existing data and expertise to develop AI-powered solutions that improve patient outcomes and reduce healthcare costs.
  • Growth opportunity 5: Expansion of the Extended Holter Patch System into new applications, such as post-operative cardiac monitoring and clinical trials, represents a significant growth opportunity. By adapting the device for these specialized applications, G Medical Innovations can target new customer segments and revenue streams. The market for cardiac monitoring devices is projected to reach $25 billion by 2028, driven by the increasing prevalence of cardiovascular diseases and the need for accurate and reliable monitoring solutions. G Medical Innovations can leverage its existing technology and expertise to capture a share of this market, offering innovative solutions for cardiac monitoring.

Oportunidades

  • Expansion into chronic disease management.
  • Strategic partnerships with healthcare providers and insurance companies.
  • Geographic expansion into new markets.
  • Development of advanced analytics and AI capabilities.

Amenazas

  • Intense competition in the medical device and telehealth industries.
  • Regulatory hurdles and reimbursement challenges.
  • Technological obsolescence.
  • Economic downturn impacting healthcare spending.

Ventajas competitivas

  • Proprietary technology in multi-sensor vital signs monitoring (Prizma).
  • Integrated solutions combining devices, monitoring services, and accessories.
  • Focus on mobile health and telemedicine solutions.
  • Established presence in the Israeli healthcare market.

Acerca de GMVDF

G Medical Innovations Holdings Ltd, established in 2014 and headquartered in Rehovot, Israel, is an early commercial stage healthcare company specializing in the development of next-generation mobile health and telemedicine solutions. The company's core offerings include the Prizma system, a multi-sensor device designed to capture vital signs and generate health trend reports, enabling proactive health management. Another key product is the Extended Holter Patch System, a patient-worn biosensor that records electrocardiography (ECG) data over extended periods, facilitating accurate cardiac monitoring. G Medical Innovations also develops a Wireless Vital Signs Monitoring System, which provides continuous, real-time monitoring of vital signs and biometrics. These solutions cater to both independent diagnostic testing facilities and individual patients seeking private monitoring services. In addition to its device offerings, G Medical Innovations provides various accessories to support its healthcare products, ensuring a comprehensive and integrated user experience. The company's focus on mobile health and telemedicine positions it to capitalize on the growing demand for remote patient monitoring and personalized healthcare solutions.

Qué hacen

  • Develops the Prizma, a multi-sensor device for vital signs monitoring and health trend reporting.
  • Offers the Extended Holter Patch System, a wearable biosensor for capturing electrocardiography (ECG) data.
  • Creates Wireless Vital Signs Monitoring Systems for continuous, real-time biometric monitoring.
  • Provides independent diagnostic testing facility monitoring services.
  • Offers private monitoring services for individual patients.
  • Supplies accessories for its healthcare products.

Modelo de Negocio

  • Sells medical devices like the Prizma and Extended Holter Patch System.
  • Generates revenue through monitoring services for diagnostic facilities.
  • Offers private monitoring services directly to patients.
  • Sells accessories related to its medical devices.

Contexto de la Industria

G Medical Innovations Holdings Ltd operates within the expanding medical devices industry, specifically targeting the mobile health and telemedicine segments. The industry is characterized by increasing demand for remote patient monitoring, driven by factors such as an aging population, rising healthcare costs, and advancements in wireless technology. The competitive landscape includes established medical device manufacturers and emerging telehealth companies. G Medical Innovations aims to differentiate itself through its integrated solutions for vital signs monitoring and ECG data capture, catering to both healthcare providers and individual patients. The global telemedicine market is projected to reach $400 billion by 2027, reflecting substantial growth potential.

Clientes Clave

  • Independent diagnostic testing facilities utilizing monitoring services.
  • Individual patients seeking private health monitoring solutions.
  • Healthcare providers integrating devices into their practice.
  • Telehealth platforms incorporating devices into their offerings.
Confianza de la IA: 65% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de G Medical Innovations Holdings Ltd (GMVDF): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para GMVDF.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para GMVDF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para GMVDF.

MoonshotScore

44/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de GMVDF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Información del mercado OTC de GMVDF

The OTC Other tier represents the lowest tier of the OTC market, indicating that G Medical Innovations Holdings Ltd may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less stringent regulatory oversight and reporting requirements.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity in OTC Other stocks like GMVDF can be highly variable and often limited. Bid-ask spreads are typically wider than those found on major exchanges, potentially leading to higher transaction costs. Trading volume may be low, making it difficult to buy or sell shares quickly without significantly impacting the price. Investors should exercise caution and be prepared for potential difficulties in executing trades.
Factores de riesgo OTC:
  • Limited financial disclosure and transparency.
  • Higher potential for fraud and manipulation.
  • Lower liquidity and wider bid-ask spreads.
  • Less stringent regulatory oversight.
  • Potential for delisting or trading suspensions.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal standing.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Monitor trading volume and price volatility.
  • Consult with a financial advisor.
  • Understand the risks associated with OTC investing.
Señales de legitimidad:
  • Company has been in operation since 2014.
  • Focus on developing innovative medical devices.
  • Presence in the mobile health and telemedicine market.
  • Development of proprietary technology (Prizma).

Preguntas Comunes Sobre GMVDF

¿Cuáles son los factores clave para evaluar GMVDF?

G Medical Innovations Holdings Ltd (GMVDF) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Innovative mobile health and telemedicine solutions.. Riesgo principal a monitorear: Potential: Intense competition in the medical device and telehealth industries.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de GMVDF?

GMVDF actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de GMVDF?

Los precios de GMVDF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre GMVDF?

La cobertura de analistas para GMVDF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en GMVDF?

Las categorías de riesgo para GMVDF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition in the medical device and telehealth industries.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de GMVDF?

La relación P/E para GMVDF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está GMVDF sobrevalorada o infravalorada?

Determinar si G Medical Innovations Holdings Ltd (GMVDF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de GMVDF?

G Medical Innovations Holdings Ltd (GMVDF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Financial data is limited due to the company's OTC listing and early commercial stage.
  • Analyst coverage is minimal, making independent assessment crucial.
Fuentes de datos

Popular Stocks